Methodology and results of real-world cost-effectiveness of
carfilzomib in combination with lenalidomide and dexamethasone
in relapsed multiple myeloma using registry data

J 2020

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

CAMPIONI, M., I. AGIRREZABAL, R. HAJEK, J. MINARIK, Luděk POUR et. al.

Basic information

Original name

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

Authors

CAMPIONI, M. (756 Switzerland, guarantor), I. AGIRREZABAL (756 Switzerland), R. HAJEK (203 Czech Republic), J. MINARIK (203 Czech Republic), Luděk POUR (203 Czech Republic, belonging to the institution), I. SPICKA (203 Czech Republic), S. GONZALEZ-MCQUIRE (756 Switzerland), P. JANDOVA (203 Czech Republic) and V. MAISNAR (203 Czech Republic)

Edition

EUROPEAN JOURNAL OF HEALTH ECONOMICS, NEW YORK, SPRINGER, 2020, 1618-7598

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.689

RIV identification code

RIV/00216224:14110/20:00115573

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s10198-019-01122-6

UT WoS

000493498500001

Keywords in English

Carfilzomib; Multiple myeloma; Cost-effectiveness; Real world; ASPIRE; Registry of Monoclonal Gammopathies

Abstract

V originále

Objective To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. Methods A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources. Results The base case incremental cost effectiveness ratio for KRd compared with Rd was euro73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of euro117,534 over their lifetime compared with euro53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively. Conclusions Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.

Citovat

CAMPIONI, M., I. AGIRREZABAL, R. HAJEK, J. MINARIK, Luděk POUR, I. SPICKA, S. GONZALEZ-MCQUIRE, P. JANDOVA and V. MAISNAR. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. EUROPEAN JOURNAL OF HEALTH ECONOMICS. NEW YORK: SPRINGER, 2020, vol. 21, No 2, p. 219-233. ISSN 1618-7598. Available from: https://dx.doi.org/10.1007/s10198-019-01122-6.

@article{1650197,
   author = {Campioni, M. and Agirrezabal, I. and Hajek, R. and Minarik, J. and Pour, Luděk and Spicka, I. and GonzalezandMcQuire, S. and Jandova, P. and Maisnar, V.},
   article_location = {NEW YORK},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s10198-019-01122-6},
   keywords = {Carfilzomib; Multiple myeloma; Cost-effectiveness; Real world; ASPIRE; Registry of Monoclonal Gammopathies},
   language = {eng},
   issn = {1618-7598},
   journal = {EUROPEAN JOURNAL OF HEALTH ECONOMICS},
   title = {Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data},
   url = {https://link.springer.com/content/pdf/10.1007/s10198-019-01122-6.pdf},
   volume = {21},
   year = {2020}
}

TY  - JOUR
ID  - 1650197
AU  - Campioni, M. - Agirrezabal, I. - Hajek, R. - Minarik, J. - Pour, Luděk - Spicka, I. - Gonzalez-McQuire, S. - Jandova, P. - Maisnar, V.
PY  - 2020
TI  - Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
JF  - EUROPEAN JOURNAL OF HEALTH ECONOMICS
VL  - 21
IS  - 2
SP  - 219-233
EP  - 219-233
PB  - SPRINGER
SN  - 16187598
KW  - Carfilzomib
KW  - Multiple myeloma
KW  - Cost-effectiveness
KW  - Real world
KW  - ASPIRE
KW  - Registry of Monoclonal Gammopathies
UR  - https://link.springer.com/content/pdf/10.1007/s10198-019-01122-6.pdf
L2  - https://link.springer.com/content/pdf/10.1007/s10198-019-01122-6.pdf
N2  - Objective To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. Methods A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources. Results The base case incremental cost effectiveness ratio for KRd compared with Rd was euro73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of euro117,534 over their lifetime compared with euro53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively. Conclusions Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.
ER  -

CAMPIONI, M., I. AGIRREZABAL, R. HAJEK, J. MINARIK, Luděk POUR, I. SPICKA, S. GONZALEZ-MCQUIRE, P. JANDOVA and V. MAISNAR. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. \textit{EUROPEAN JOURNAL OF HEALTH ECONOMICS}. NEW YORK: SPRINGER, 2020, vol.~21, No~2, p.~219-233. ISSN~1618-7598. Available from: https://dx.doi.org/10.1007/s10198-019-01122-6.

Detailed Information on Publication Record